The HCG team at Bengaluru treated its first patient after successful training and certification
Scandanavia-based ChemoTech and HCG have engaged in an agreement to perform a scientific evaluation of IQwave and the TSE (Tumour Specific Electroporation). The evaluation is led by HCGs Department of Translational Medicine. After the training and certification of doctors and nurses that took place in early November at HCG’s cancer centre in Bengaluru India, this important collaboration could finally begin.
After a successful training and certification of doctors and nurses at HCG Cancer Centre in Bengaluru in India, the team treated its first patient after the lifting of the COVID-19 lockdown.
“Even if the COVID–19 situation is far from over we are happy that this programme was able to take off. This evaluation is the first step in a larger launch within the HCG group. It is therefore of great importance to both us and the HCG team,” says Mohan Frick, CEO, ChemoTech
“Despite the risks posed by COVID-19, we are happy that our oncology team has been trained and designated a certified centre for the TSE therapy. Our plan is now to accelerate the evaluation programme and the collaboration with ChemoTech. Last week we treated the first patient since the COVID-19 lockdown,” says Dr Suhail Sayeed Mufti, Director at the Department of Translational Medicine & Therapeutics, HCG.
